#USA #Anixa Biosciences #CAR-T therapy #San Jose, California #Ovarian Cancer

Anixa Biosciences Achieves a Significant Milestone in Ovarian Cancer CAR-T Trial

Anixa Biosciences, Inc. has announced encouraging news from its Phase 1 clinical trial focusing on a novel CAR-T therapy aimed at treating recurrent ovarian cancer. The company recently revealed that a patient treated with their genetically engineered T-cell therapy exhibited no progression of cancer for a remarkable three months following treatment. This milestone marks the first instance of stable disease noted in this clinical trial, a significant achievement for the company and its research team.

Overview of the Clinical Trial

The trial assesses liraltagene autoleucel (lira-cel), Anixa’s groundbreaking therapy that specifically targets the follicle-stimulating hormone receptor (FSHR). This receptor is present on ovarian cancer cells but minimally expressed in healthy tissues, which makes it a compelling target for therapy. The ongoing study is designed to evaluate the safety and tolerability of escalating doses of lira-cel, while also looking for signs of initial efficacy in adult women with recurrent ovarian cancer who have already undergone at least two prior treatments.

Dr. Amit Kumar, the Chairman and CEO of Anixa Biosciences, expressed optimism regarding the trial's progress, stating, “This Phase 1 study is primarily designed to evaluate safety. However, we are buoyed by the early anecdotes surrounding overall survival and the fact that one patient demonstrated stable disease for three months post-treatment.” Additionally, multiple patients in the trial have survived for over a year, with one even surpassing the two-year mark, marking a significant breakthrough in efficacy for a type of cancer known for its poor prognosis.

The Role of Moffitt Cancer Center

The trial is conducted in conjunction with the Moffitt Cancer Center, a renowned institution in cancer immunotherapy. Under the leadership of Dr. Robert Wenham, Chair of the Gynecologic Oncology Program at Moffitt and the trial’s principal investigator, the team hopes to see an improvement in patient outcomes as they continue to observe results. Dr. Wenham emphasized the importance of transitioning patients from progressive disease to stable disease and ultimately aiming for responses that can be categorized as partial or even complete.

Unique Aspects of lira-cel

What sets lira-cel apart from other therapies is its unique mechanism of action. Unlike conventional CAR-T therapies, which utilize an antibody fragment, lira-cel is designed to harness the natural ligand of the FSHR receptor, allowing it to bind directly to the tumor cell. This presents a potential breakthrough in terms of specificity and safety, diminishing harm to healthy tissues.

Currently, there have been no reports of dose-limiting toxicities amongst enrolled patients, which is a crucial factor in the ongoing assessment of the therapy's safety profile. As the trial progresses, further analysis of the presence and longevity of CAR-positive cells will also take place, providing insight into the therapy's potential long-term effects.

Future Perspectives

As Anixa Biosciences looks to the future, their collaborative research model—forging partnerships with prestigious institutions like Moffitt and the Cleveland Clinic—enables them to continually evaluate and develop promising cancer therapies. The company is also focused on advancing additional vaccines aimed at various cancers, including those of the breast and prostate, utilizing technologies that immunize against proteins prevalent in certain cancers.

In conclusion, Anixa's recent findings serve as a hopeful beacon for patients battling ovarian cancer and signal the potential for innovative treatment pathways. The clinical trial has opened the door not only for a specific therapy targeting ovarian cancer but has also highlighted the importance of personalized medicine in oncology. As this remarkable journey continues, the focus remains on not only achieving stability in patients’ conditions but ideally transforming their prognosis to one of lasting remission.

For those interested in following the progress of Anixa Biosciences, updates can be monitored through their official website and various social media platforms.